patient subgroup...
subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
azithromycin - versus control - for COVID 19 hospitalized
pdf
xlsx
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 death D28 0.98 [0.89, 1.08]< 1 0% 2 studies (2/-) 65.3 % some concern not evaluable moderate crucial - deaths 0.97 [0.88, 1.06]< 1 0% 6 studies (4/2) 76.4 % moderate not evaluable moderate crucial - deaths (time to event analysis only) 0.97 [0.83, 1.13]< 1 17% 3 studies (2/1) 65.0 % moderate not evaluable moderate crucial - clinical improvement 0.76 [0.56, 1.04]> 1 0% 2 studies (2/-) 4.2 % some concern not evaluable moderate important - clinical improvement (14-day) 0.76 [0.56, 1.04]> 1 0% 2 studies (2/-) 4.2 % some concern not evaluable moderate important - clinical improvement (28-day) 0.70 [0.47, 1.04]> 1 0% 1 study (1/-) 3.9 % NA not evaluable important - clinical improvement (7-day) 0.92 [0.69, 1.22]> 1 0% 2 studies (2/-) 27.5 % some concern not evaluable moderate important - death or ventilation 0.95 [0.87, 1.03]< 1 0% 1 study (1/-) 88.3 % NA not evaluable important - hospital discharge 1.04 [0.98, 1.10]> 1 0% 1 study (1/-) 90.8 % NA not evaluable important - mechanical ventilation 1.00 [0.62, 1.61]< 1 32% 3 studies (3/-) 49.5 % some concern not evaluable moderate important - radiologic improvement (14-day) 1.64 [0.94, 2.88]> 1 0% 1 study (1/-) 95.8 % NA not evaluable important - viral clearance 715.00 [12.94, 39513.71]> 1 0% 1 study (1/-) 99.9 % NA not evaluable important - ICU admission 0.25 [0.05, 1.28]< 1 0% 1 study (1/-) 95.1 % NA not evaluable non important - safety endpoints 00 cardiac arrest 0.64 [0.27, 1.54]< 1 0% 1 study (-/1) 84.0 % NA not evaluable important - related SAE (TRSAE) 1.24 [0.50, 3.11]< 1 0% 1 study (1/-) 32.0 % NA not evaluable important - serious adverse events 1.19 [0.82, 1.73]< 1 0% 2 studies (2/-) 17.8 % some concern not evaluable moderate important - abnormal ECG findings 0.95 [0.47, 1.93]< 1 0% 1 study (-/1) 55.6 % NA not evaluable non important - adverse events 1.21 [0.82, 1.78]< 1 0% 1 study (1/-) 17.4 % NA not evaluable non important - arrhythmia 0.92 [0.74, 1.15]< 1 0% 3 studies (2/1) 76.8 % moderate not evaluable moderate non important - long QT 0.90 [0.56, 1.43]< 1 0% 1 study (1/-) 67.1 % NA not evaluable non important - renal impairment 1.43 [1.00, 2.05]< 1 0% 2 studies (2/-) 2.5 % some concern not evaluable moderate non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.